title: Ovarian cancer vaccine candidate DPX-Survivac: positive interim results from phase 1.
authors: Eva M
authors: EM
authors: Riedmann
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D017321:Clinical Trials, Phase I as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D010051:Ovarian Neoplasms / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D007155:Immunologic Factors; D003520:Cyclophosphamide